®
Clinical Evidence
Independent MMRM analysis by Lisa Kang, MSPH, Harvard Medical School, spanning 17,000+ real-world users across 32 months in 147 countries.
17,000+
Users Analyzed (147 Countries, 32 Months)
39%
Stress Reduction by Day 7
d = 0.80
Large Effect Size (Cohen's d)
7 Days
To Primary Outcome
Independent MMRM Efficacy Analysis
Analysis demonstrates large effect sizes for stress relief, achieved in days rather than months, with no clinician required.
TimepointNReductionEffect Size (d)p-value
Day 210,20223%0.71 (medium-large)< 0.001
Day 74,15839%0.80 (large)< 0.001
Day 142,48144%0.85 (large)< 0.001
Day 3596952%0.86 (large)< 0.001
Analysis uses MMRM under an intent-to-treat framework across all users with measurable baseline stress (96.5% of population); sensitivity analyses confirm dropout is engagement-driven (all p > 0.20).
Replicated in clinician-referred cohort with no paywall (N = 284, Δd = +0.006).
MMRM Stress Trajectory
Day-level MMRM estimated marginal means show a rapid initial decline followed by sustained improvement through Day 35.
MMRM Stress Trajectory: Mild+ population (N = 16,487), d=0.80 by Day 7.
MMRM stress trajectory for the Mild+ population (N = 16,487). Blue line shows estimated marginal means; gray bars show check-in retention at each timepoint.
NEUROFIT vs. Leading Digital Health Apps
NEUROFITLeading Digital Health Apps
Time to results7 days4–6 weeks (limited evidence)
Effect sized = 0.80d = 0.26–0.56†
PrivacyFully private on phonePrivate
†App range: pooled g = 0.26–0.30 (Linardon et al., 2019; 2024) to d = 0.56 peak (Mehta et al., 2021).
NEUROFIT figures are within-subject pre-post estimates from real-world use; published app benchmarks are drawn from randomized controlled trials, where effect sizes are typically smaller.
NF8 Psychometric Validation
Outcomes validated against gold-standard clinical scales — PHQ-9, GAD-7, and DASS-21.
ScaleCorrelationp-valueMeasures
PHQ-9r = 0.63< 0.001Depression
GAD-7r = 0.57< 0.001Anxiety
DASS-21r = 0.52< 0.001Stress / Anxiety / Depression
PCL-5 (est.)†r ≥ 0.47—PTSD (direct validation in progress)
Cronbach's α = 0.80. Biomarker convergent: HRV, heart rate, and breathing rate (n=100,345 PPG observations from 12,845 users).
†PCL-5 transitive estimate via PHQ-9 ↔ PCL-5 correlation (Bovin et al., 2016). Direct validation in progress.
Correlations reflect convergent validity of the NF8 as a somatic stress measure, rather than diagnostic capability.
Embodiment vs. Mindset
EmbodimentMindsetEmbodimentMindset
NEUROFIT's embodiment approach speaks to 80% of the nervous system. Mindset only speaks to the other 20%.
Evidence-based somatic movements proven to reduce stress. -Business Insider
NEUROFIT eased my stress in ways meditation never has -Well and Good
NEUROFIT is a SHAPE Magazine Groundbreaking Recovery Innovation.
Informed by neuroscience research from leading universities. View References →
Full whitepaper with methods, psychometric validation, and biomarker analysis available on request.
Balance your nervous system, reduce stress, and feel your best with NEUROFIT.
Nervous System Fitness®
NEUROFIT has been accepted into the Microsoft For Startups Program.
NEUROFIT has been accepted into the NVIDIA Inception Program.
NEUROFIT has been accepted into the AWS Activate Program.
Products
NEUROFIT AppVitals SDK
Practitioners & Teams
coachOS™ DashboardNEUROFIT For Teams/OrganizationsNervous System Dysregulation QuizPersonalized Somatic Exercise ToolNEUROFIT Nervous System Book (PDF)Nervous System + Somatics Glossary
Top Glossary + Blog Articles
Research
App EfficacyStress Outcomes WhitepaperVitals Validation Report (PDF)
Company
About UsWall Of Love 🤍PressAccessibilityRecent ReleasesLegalPrivacy Policy
Xama Technologies, Inc. (dba NEUROFIT)
651 North Broad Street, Suite 206
Middletown, DE, USA 19709
SAM.gov Registration:
UEI: C6T8P1MJU3D5
CAGE: 19ML0
DUNS: 117864242
care@neurofit.apppress@neurofit.appcontact@neurofit.app
© NEUROFIT 2026•All Rights Reserved
NEUROFIT®, Nervous System Fitness® and Coach Copilot® are registered trademarks of Xama Technologies, Inc. in the United States and other jurisdictions.
The NEUROFIT products, programs and services are intended solely to help users maintain a state of wellness and encourage a healthy lifestyle. NEUROFIT products, programs and services are neither designed nor intended for use in the diagnosis, cure, management, mitigation, prevention, or treatment of any disease or medical condition.
As always, we highly recommend that speak with your trusted healthcare professional before making any health-related decisions or using any health-related products or services.